Mike

Dr. Mike Thompson

CEO

Originally coming from Florida, Mike graduated with a B.Sc. cum laude in biochemistry from the University of Florida in 2010. During his time there Mike spent several years working on organic and inorganic synthesis. In 2011, he moved to Dresden to pursue his doctoral work in the lab of Professor Yixin Zhang at the B CUBE Center for Molecular Bioengineering. Mike’s time there was spent working on DNA- and synethtic polymer-based supramolecular structures for biotechnological applications, culminating in a thesis defense and awarding of a Ph.D. magna cum laude in 2015. From 2015, Mike became project leader of DyNAbind’s Exist-Forschungstransfer grant team, steering the team to successful company foundation in 2017. Mike comes from a family of technology entrepreneurs, giving him insight into the start-up process from a young age.

 

Norbert

Dr. Norbert Höfgen

COO

Norbert Höfgen studied Chemistry and subsequently performed his doctorate in organic Chemistry at the Technische Universität Dresden, earning his Ph.D. in 1987. Directly after completion of his doctoral studies, he joined the Arzneimittelwerk Dresden GmbH as senior scientist, and later as group leader Head of Medicinal Chemistry. Thanks to a management buyout transition, in 2002 Norbert Höfgen became co-founder and member of the management team of elbion AG, leading programs to develop new treatments for a wide spectrum of diseases and pain. Besides his project management activities, he also managed the companies’ intellectual properties, developed business models and coordinated international collaborations and licensing activities with various major pharmaceutical companies as well as universities and research institutes.

 

Francesco

Dr. Francesco Reddavide

Head of Research and Development

Francesco Reddavide graduated from the University of Bari (Italy) with a M.Sc. in Medical and Pharmaceutical Biotechnology in 2011, with a master thesis project on the development of a microfluidic device performing PCR reactions, in the group of Prof. Dario Pisignano (National Nanotechnology Laboratory CNR-Nano, Lecce/Italy). The device was used as a lab-on-a-chip platform to detect toxin producing pathogens on food. Afterwards, he joined the lab of Yixin Zhang at the TU Dresden, to perform his doctoral studies developing DNA-encoded dynamic combinatorial chemical libraries and participating in the development of the regenerative chip for DNA-encoded compound hit-validation. He is co-author of the dynamic DECL patents and of peer-reviewed publications about regenerable biosensor chip technology applications.

Scientific Advisors

Yixin

 

Professor Yixin Zhang

From his Ph.D. with Prof. Gunter Fischer (Max Planck Research Unit for Enzymology of Protein Folding, Halle, Germany) to his postdoctoral work with Prof. Dario Neri at the Institute of Pharmaceutical Sciences (ETH Zurich, Switzerland) to running his own lab, Yixin Zhang has explored and developed innovative chemical approaches to drug discovery and modification. He contributed to fundamental publications about the development and application of DECLs during his work at the ETH Zurich. He is an expert in drug design, drug screening, and medicinal chemistry, with a particular focus on immunosuppressive drugs. Currently, Yixin Zhang’s research covers a broad range of pharmaceutical and biomedical topics, from protein-drug interaction to biomaterials. Work in his lab led to the DyNAbind Path-Coding algorithm, dynamic chemical model library and the regenerable biosensor chip technology patent applications.

luca mannocci

Dr. Luca Mannocci

Luca Mannocci has over 10 years’ experience in DNA-Encoded Chemical library technologies and its industrial applications in drug discovery field. Luca Mannocci has an extensive background in isolation, characterization and optimization of low molecular weight hit compounds, as well as in chemical modification and conjugation of biomacromolecules. He studied Chemistry at the University of Pisa with a focus on the synthesis and characterization of pharmaceutically relevant naturally occurring compounds. In 2008 earned the Ph.D. in Chemistry under the supervision of Professor Dario Neri in the Institute of Pharmaceutical Sciences at ETH Hönggerberg, with a dissertation on the first implementation of high-throughput sequencing for the decoding of various DNA-encoded chemical library formats.  Luca Mannocci is author of several publications on DECL-technology in peer-reviewed journals  as well as in drug discovery books.